Wall Street Zen Upgrades T Stamp (NASDAQ:IDAI) to Hold
T Stamp (NASDAQ:IDAI – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday. Separately, Maxim Group boosted their price objective on T Stamp from $8.00 to $12.00 and gave the stock a “buy” rating in a […]
Wall Street Zen Upgrades Onespan (NASDAQ:OSPN) to “Buy”
Onespan (NASDAQ:OSPN – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday. Several other research firms also recently weighed in on OSPN. DA Davidson dropped their price target on Onespan from $15.00 to $13.00 and set a “neutral” […]
Wall Street Zen Upgrades AIRO Group (NASDAQ:AIRO) to “Hold”
AIRO Group (NASDAQ:AIRO – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday. Several other equities analysts also recently commented on AIRO. Cantor Fitzgerald dropped their price objective on shares of AIRO Group from $35.00 to $20.00 […]
Wall Street Zen Upgrades PowerBank (NASDAQ:SUUN) to “Hold”
PowerBank (NASDAQ:SUUN – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday. Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PowerBank in a research report on Tuesday, October 14th. One research analyst has rated […]
Wall Street Zen Upgrades OptimizeRx (NASDAQ:OPRX) to Strong-Buy
OptimizeRx (NASDAQ:OPRX – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Sunday. Other equities analysts have also recently issued research reports about the stock. Zacks Research raised shares of OptimizeRx from a “hold” rating to a “strong-buy” […]
Wall Street Zen Upgrades LKQ (NASDAQ:LKQ) to Buy
LKQ (NASDAQ:LKQ – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday. Other analysts have also issued research reports about the stock. Barclays began coverage on shares of LKQ in a report on Tuesday, November 11th. They set an […]
Wall Street Zen Upgrades Stitch Fix (NASDAQ:SFIX) to “Buy”
Stitch Fix (NASDAQ:SFIX – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday. Other equities research analysts have also recently issued research reports about the company. Zacks Research cut Stitch Fix from a “strong-buy” rating to a […]
Wall Street Zen Upgrades Yuanbao (NASDAQ:YB) to Buy
Yuanbao (NASDAQ:YB – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday. Separately, Weiss Ratings restated a “hold (c)” rating on shares of Yuanbao in a research note on Monday, December 8th. One research analyst has rated […]
Wall Street Zen Upgrades Texas Roadhouse (NASDAQ:TXRH) to Hold
Texas Roadhouse (NASDAQ:TXRH – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday. Several other analysts have also issued reports on TXRH. Stephens reduced their price target on shares of Texas Roadhouse from $175.00 to $168.00 […]
Wall Street Zen Upgrades Ekso Bionics (NASDAQ:EKSO) to Hold
Ekso Bionics (NASDAQ:EKSO – Get Free Report) was upgraded by Wall Street Zen to a “hold” rating in a note issued to investors on Saturday. Other analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ekso Bionics in a report on Monday, December 8th. HC […]
Wall Street Zen Upgrades Immix Biopharma (NASDAQ:IMMX) to “Hold”
Immix Biopharma (NASDAQ:IMMX – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday. Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in […]
last updated on 22 Dec 13:11